Literature DB >> 2866493

Comparison of buspirone and diazepam in generalized anxiety disorder.

A F Jacobson, R A Dominguez, B J Goldstein, R M Steinbook.   

Abstract

A total of 66 outpatients meeting Diagnostic and Statistical Manual (DSM-III) criteria for generalized anxiety disorder began treatment in a randomized double-blind study that compared the efficacy and safety of buspirone and diazepam. Thirty-nine outpatients completed the 4-week trial. Both drugs were administered in a 1:1 dosage ratio; the daily prescribed dose did not exceed 40 mg. The mean daily dose of buspirone prescribed throughout the study was significantly higher than that of diazepam. Diazepam had a significantly earlier onset of efficacy than buspirone, although both drugs were equivalent after 4 weeks of treatment. Adverse reactions were more frequent in the diazepam group. Total scores from the Hamilton anxiety scale and physician's global ratings show that diazepam was significantly superior to buspirone during the initial 2 weeks of treatment. These findings are further corroborated by the results of patients' self-rated scales.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866493     DOI: 10.1002/j.1875-9114.1985.tb03430.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

1.  Convergence on reduced stress behavior in the Mexican blind cavefish.

Authors:  Jacqueline S R Chin; Claude E Gassant; Paloma M Amaral; Evan Lloyd; Bethany A Stahl; James B Jaggard; Alex C Keene; Erik R Duboue
Journal:  Dev Biol       Date:  2018-05-25       Impact factor: 3.582

2.  Evaluation of the dependence potential of the selective 5-H1A agonist ipsapirone in rats and of its effects on benzodiazepine withdrawal.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Anticonflict and discriminative stimulus effects in the pigeon of a new methoxy-chroman 5-HT1A agonist, (+)S 20244 and its enantiomers (+)S 20499 and (-)S 20500.

Authors:  J E Barrett; E H Gamble; L Zhang; B Guardiola-Lemaitre
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

4.  Phasic and sustained fear are pharmacologically dissociable in rats.

Authors:  Leigh Miles; Michael Davis; David Walker
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

5.  The diagnosis and treatment of generalized anxiety disorder.

Authors:  Borwin Bandelow; Reinhard Boerner J; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-04-26       Impact factor: 5.594

6.  Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression : results of a comparatively high dosage trial.

Authors:  K Nishitsuji; H To; Y Murakami; K Kodama; D Kobayashi; T Yamada; C Kubo; K Mine
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 7.  Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.

Authors:  K L Goa; A Ward
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 8.  Azapirones for generalized anxiety disorder.

Authors:  C A Chessick; M H Allen; Me Thase; A B C Batista Miralha da Cunha; F F K Kapczinski; M S M L de Lima; J J S S dos Santos Souza
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.